NEW YORK, NY – For decades, the role of regulatory T (Treg) cells in cancer has been a perplexing paradox, particularly in colorectal cancer (CRC). While these immune cells, often described as the "brakes" of the immune system, are typically associated with worse patient outcomes in most solid tumors due to their ability to suppress anti-cancer responses, their abundance in colorectal tumors has bafflingly correlated with improved survival. This perplexing inconsistency has long stumped oncologists and immunologists, hindering the development of effective immunotherapies for the disease.
Now, a groundbreaking study from researchers at the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering Cancer Center (MSK) has decisively resolved this long-standing enigma. The pivotal discovery: Treg cells are not a monolithic entity. Instead, the team has identified two distinct subtypes of Treg cells within colorectal tumors, each playing an opposing role in tumor progression. One subtype actively restrains tumor growth, while the other fuels it. This nuanced understanding not only explains the colorectal cancer paradox but also opens a promising new avenue for targeted immunotherapy, particularly for the most common forms of the disease that currently respond poorly to existing treatments.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," states Alexander Rudensky, PhD, co-senior author of the study and Chair of the Immunology Program at MSK, and a Howard Hughes Medical Institute Investigator. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches in cancer treatment."
Published in the prestigious scientific journal Immunity, these findings hold significant implications, not only for improving immunotherapy strategies for the majority of colorectal cancer patients but also potentially for other cancers arising in "barrier tissues" like the skin, stomach lining, mouth, and throat, which share similar immune environments.
The Enigmatic Role of Regulatory T Cells: Immune Brakes and Cancer Conundrums
Regulatory T cells, or Tregs, are a crucial component of the immune system, primarily tasked with maintaining "immune tolerance." This vital function ensures that the immune system distinguishes between harmful pathogens and benign entities, preventing autoimmune reactions where the body mistakenly attacks its own healthy tissues. In essence, Tregs act as gatekeepers, dampening excessive inflammatory responses and maintaining a delicate balance within the immune landscape.
However, in the context of cancer, this immunosuppressive capability often becomes a double-edged sword. Tumors frequently hijack these natural immune brakes to evade detection and destruction by the body’s own defenses. By recruiting and expanding populations of Tregs, cancer cells can create an immunosuppressive microenvironment that stifles the activity of potent anti-tumor immune cells, such as cytotoxic CD8+ T cells, allowing the tumor to grow unchecked. This is why, in a vast majority of solid tumors, a higher infiltration of Tregs is generally associated with more aggressive disease progression and poorer patient outcomes. The more brakes applied to the immune system, the less effectively it can fight the cancer.
Colorectal cancer, however, has consistently defied this generalization. For years, clinicians and researchers observed that patients with a greater number of Tregs within their colorectal tumors often experienced longer survival times. This counterintuitive correlation has been a source of intense scientific curiosity and frustration, as it complicated efforts to apply universal immunotherapy strategies that aim to broadly reduce Treg activity. Understanding this unique immune landscape was paramount to developing effective treatments for CRC, the second leading cause of cancer-related death globally when men and women are combined, according to the American Cancer Society.
Decades of Discovery: Tracing the Path to Understanding Immune Tolerance
The current breakthrough is not an isolated finding but rather the culmination of more than two decades of pioneering research by Dr. Rudensky, widely recognized as one of the world’s foremost experts on regulatory T cells. His laboratory’s foundational work has been instrumental in establishing the critical role of Tregs in maintaining immune tolerance, elucidating how these specialized cells are generated, how they exert their regulatory functions, and how they ultimately influence various disease states, including cancer.
Over the years, Dr. Rudensky’s team has systematically deconstructed the molecular and cellular mechanisms governing Treg biology. Their investigations have illuminated the complex signaling pathways and transcriptional programs that dictate Treg development and function, revealing the intricate network through which these cells exert their profound influence on the immune system. This deep-seated understanding of Treg identity and behavior formed the essential bedrock upon which the current study was built, providing the conceptual framework and experimental tools necessary to probe the nuances of Treg populations within the tumor microenvironment.
The critical question that persisted, however, was why colorectal cancer presented such a stark deviation from the established paradigm of Treg function in other malignancies. Was there something inherently different about the Tregs themselves, or about the specific immune environment of the colon? The MSK team embarked on an ambitious research journey to answer this very question, leveraging advanced genomic and cellular techniques to dissect the immune landscape of colorectal tumors with unprecedented resolution.
The study was led by a talented team of first authors: Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, who served as the study’s other senior author. This collaborative effort, combining experimental immunology with sophisticated computational analysis, was crucial for unraveling the complexity of Treg heterogeneity.
A Deeper Dive into Colorectal Cancer: Addressing Unmet Needs
The researchers specifically focused on the most prevalent form of colorectal cancer, which accounts for approximately 80% to 85% of all cases. This subtype is characterized as microsatellite stable (MSS) with proficient mismatch repair (MMRp), meaning its DNA remains relatively stable. Unfortunately, this group of cancers has historically shown limited response to checkpoint inhibitor immunotherapies, a revolutionary class of drugs that unleash the immune system’s anti-cancer potential by blocking inhibitory signals.
In stark contrast, earlier research at MSK and elsewhere demonstrated that checkpoint inhibitors can be remarkably effective against the opposite tumor type: cancers with high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd). These tumors, characterized by a high number of DNA mutations, are often brimming with immune cells and respond robustly to immunotherapy, frequently allowing patients to avoid aggressive treatments like surgery, chemotherapy, and radiation. The disparate responses highlight a critical unmet need for effective immunotherapeutic strategies for the majority of CRC patients with MSS-MMRp disease. The MSK study sought to bridge this therapeutic gap by understanding the unique immunological features of MSS-MMRp colorectal cancer.
Unveiling the Dual Nature: Two Distinct Treg Subtypes with Opposing Effects
To unravel the complexities distinguishing common colorectal cancers, the research team employed a sophisticated mouse model meticulously developed at MSK. This model closely mirrors the genetic alterations, behavioral characteristics, and intricate immune environment observed in human colorectal tumors, providing a highly relevant platform for their investigations.
Through detailed analysis, they made a pivotal discovery: tumor-associated Treg cells are not uniform but rather fall into two principal categories. One group of these Tregs produces a crucial signaling molecule, or cytokine, known as interleukin-10 (IL-10). The other group, notably, does not. This distinction proved to be the key to unlocking the colorectal cancer paradox.
In a series of meticulously designed experiments, the researchers selectively removed each of these Treg groups from the mouse models, allowing them to precisely observe the impact of each subtype on tumor growth dynamics. The results were striking and unequivocally demonstrated their opposing roles:
The Protective Role of IL-10-Positive Tregs
The IL-10-positive Treg cells were found to play a beneficial, tumor-restraining role. Their primary mechanism of action involves reducing the activity of another immune cell type known as Th17 cells. Th17 cells produce interleukin-17 (IL-17), a cytokine that acts as a potent growth signal for tumors, promoting their proliferation and angiogenesis (new blood vessel formation). By dampening Th17 cell activity and consequently IL-17 production, IL-10-positive Tregs effectively slow down tumor progression. Importantly, these protective Treg cells were observed to be more commonly situated in the healthy tissue surrounding the tumor rather than deep within the tumor mass itself. When the researchers selectively eliminated these IL-10-positive Treg cells from the mouse models, tumors grew significantly more quickly, underscoring their critical protective function.
The Detrimental Impact of IL-10-Negative Tregs
Conversely, the IL-10-negative Treg cells exhibited the opposite effect, actively promoting tumor growth. These cells were found to powerfully suppress the activity of crucial anti-cancer immune defenders, most notably CD8+ T cells. CD8+ T cells are often referred to as "killer T cells" due to their remarkable ability to directly identify and destroy cancer cells. By inhibiting these potent immune effectors, IL-10-negative Tregs create an immunosuppressive environment that allows the tumor to thrive. This harmful subtype was predominantly localized within the tumor itself, where it could most effectively neutralize anti-tumor responses. When the IL-10-negative Treg cells were selectively eliminated, the tumors became markedly smaller, demonstrating their significant role in fueling tumor progression.
Human Validation: Patient Data Confirms the Bifurcation
To ensure the relevance of their findings to human disease, the MSK team rigorously confirmed these results using tumor samples obtained from actual colorectal cancer patients. In these human samples, they successfully identified the same two distinct populations of IL-10-positive and IL-10-negative Treg cells, mirroring their observations in the mouse models.
Further bolstering their conclusions, the researchers analyzed the clinical outcomes of over 100 colorectal cancer patients. The results were compelling: patients whose tumors contained higher levels of the beneficial IL-10-positive Treg cells consistently exhibited longer survival times. Conversely, patients whose tumors were enriched with the detrimental IL-10-negative Treg cells experienced poorer outcomes. This direct correlation between Treg subtype prevalence and patient prognosis provided robust clinical validation for the experimental findings.
"This research shows how important these positive cells are," Dr. Huang emphasizes. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones." This sentiment encapsulates the paradigm shift brought about by the study: moving away from a broad, indiscriminate targeting of all Tregs towards a precision approach that distinguishes between beneficial and detrimental immune subsets.
A New Therapeutic Frontier: Targeting CCR8 for Precision Immunotherapy
The implications of these findings extend beyond mere academic understanding; they suggest a highly promising and actionable path forward for improving treatment for the vast majority of colorectal cancer patients, particularly those with MSS-MMRp disease who currently lack effective immunotherapeutic options.
A critical discovery was that the harmful, IL-10-negative Treg cells express high levels of a specific protein on their surface called CCR8. These are precisely the cells that actively suppress the anti-tumor immune response and are predominantly found within the tumor microenvironment. This makes CCR8 an ideal target for selective therapeutic intervention.
This insight builds upon earlier foundational work from Dr. Rudensky’s laboratory, notably led by breast cancer surgeon George Plitas, MD. That prior research had already demonstrated that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human malignancies. This earlier work had provocatively suggested that antibodies designed to specifically bind to and deplete CCR8-expressing cells could be employed to selectively remove these harmful Treg populations. The beauty of this approach lies in its precision: it could allow the immune system to launch a more effective attack against tumors while leaving the beneficial, protective Treg cells intact, thus minimizing potential autoimmune side effects.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky explains, highlighting the global impact and recognition of MSK’s innovative research. Multiple clinical trials are currently underway at MSK and other leading institutions, testing this novel approach both as a standalone therapy and in combination with existing immunotherapies. The new study on colorectal cancer significantly strengthens the scientific rationale for deploying this strategy in CRC and potentially expanding its application to a wider spectrum of cancers.
Beyond Colorectal Cancer: Broader Implications for Barrier Tissues
The MSK team did not stop at colorectal cancer. To investigate the broader applicability of their findings, they meticulously examined a large dataset comprising T cells from 16 different cancer types. Their comprehensive analysis revealed that similar divisions between IL-10-positive and IL-10-negative Treg cells were present in several other cancers affecting "barrier tissues" such as the skin (e.g., melanoma), and the linings of the mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," notes Dr. Mitra, who spearheaded the intricate data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. This commonality suggests a shared immunological landscape and, crucially, a shared vulnerability to therapeutic intervention. The team posits that therapies engineered to remove IL-10-negative Treg cells in colorectal cancer could very well prove effective against these other malignancies arising in barrier tissues, dramatically expanding the potential impact of this discovery.
Metastatic Disease: A Shifting Immune Landscape Requires Tailored Strategies
An additional, critical nuance emerged when the researchers investigated colorectal cancer that had metastasized, specifically to the liver. In these advanced metastatic tumors, a significantly different immune pattern was observed. The detrimental IL-10-negative Treg cells were found to greatly outnumber the helpful IL-10-positive cells. This stark imbalance had a profound functional consequence: unlike in primary tumors, where selective targeting was paramount, removing all Treg cells in the context of liver metastases actually caused these tumors to shrink.
This finding underscores the dynamic and context-dependent nature of the tumor immune microenvironment. It highlights the imperative for treatment strategies to account not only for the specific tissue involved but also for the stage of the disease. A "one-size-fits-all" approach to Treg modulation may not be optimal; instead, precision immunotherapy will likely require tailored strategies that consider the unique immunological characteristics of primary versus metastatic lesions.
Paving the Way for Precision Immunotherapy
The findings from Memorial Sloan Kettering Cancer Center represent a significant leap forward in understanding the complex interplay between the immune system and cancer. By resolving the long-standing paradox of Treg cells in colorectal cancer, the research team has not only provided a clear explanation for a puzzling biological phenomenon but has also laid the groundwork for a new generation of precision immunotherapies.
The shift from broadly suppressing all Tregs to selectively targeting the detrimental subtype, while preserving the beneficial ones, heralds a more refined and potentially more effective approach to cancer treatment. For the millions of patients with MSS-MMRp colorectal cancer, for whom current immunotherapies have largely been ineffective, this research offers a renewed sense of hope. The ongoing clinical trials evaluating CCR8-depleting antibodies are a testament to the translational potential of this discovery, bringing the promise of targeted Treg modulation closer to patient care.
As Dr. Rudensky aptly summarizes, "This research points to the critical importance of developing therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones." The implications extend beyond colorectal cancer, offering a blueprint for understanding and manipulating the immune microenvironment in other challenging malignancies, particularly those arising in barrier tissues. This breakthrough marks a pivotal moment in the quest for more personalized, effective, and less toxic cancer treatments, ushering in an era of truly precision immunotherapy.
Authorship, Funding, and Disclosures:
Additional authors contributing to this seminal research include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
The Integrated Genomics Operation and the Single Cell Research Initiative at MSK played instrumental roles in the execution and analysis of this extensive research.
This study was generously supported by funding from the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
Dr. Rudensky has disclosed serving on scientific advisory boards and holding equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity.
It is further disclosed that Dr. Rudensky and Dr. Plitas are inventors on patents and patent applications held by MSK related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8.
About the Author
